Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 55 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Exemestane and tamoxifen Clear all
Completed Phase 3 Interventional Results available

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066703
View directory record Official record
Conditions
Breast Cancer
Interventions
exemestane, tamoxifen, triptorelin
Drug
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 65 Years · Female only
Enrollment
2,672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2024
U.S. locations
139
States / cities
Burbank, California • La Jolla, California • Mission Hills, California + 106 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Recruiting Phase 2 Interventional

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

NCT02476786
View directory record Official record
Conditions
Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
Interventions
FACT-B, Goserelin, Anastrozole, Exemestane, Fulvestrant, Tamoxifen, Archived tissue collection
Behavioral · Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
70 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

NCT04129216
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen Citrate, Letrozole, Exemestane, Blueprint, Mammaprint
Drug · Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 6, 2026, 1:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Active, not recruiting Phase 2 Interventional

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

NCT05607004
View directory record Official record
Conditions
Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions
(Z)-endoxifen, goserelin
Drug
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690
View directory record Official record
Conditions
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin
Drug · Other · Procedure + 1 more
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 65 Years · Female only
Enrollment
3,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2024
U.S. locations
480
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Active, not recruiting Phase 2 Interventional

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

NCT04569747
View directory record Official record
Conditions
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Interventions
Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY
Combination Product · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
32
States / cities
Stamford, Connecticut • Miami, Florida • Atlanta, Georgia + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Active, not recruiting Phase 2 Interventional

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NCT05826964
View directory record Official record
Conditions
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

NCT02057133
View directory record Official record
Conditions
Breast Neoplasms
Interventions
LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, Fulvestrant, Pertuzumab, Loperamide, Endocrine therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
13
States / cities
Rogers, Arkansas • La Jolla, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors

NCT01831076
View directory record Official record
Conditions
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Exemestane, Exemestane and tamoxifen
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 6, 2026, 1:04 PM EDT
Completed Phase 2 Interventional

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

NCT05150652
View directory record Official record
Conditions
Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
Interventions
Anastrozole 1mg, Letrozole 2.5mg, Exemestane 25 mg, Tamoxifen
Drug
Lead sponsor
Irada Ibrahim-zada
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

NCT03691493
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Anastrozole, Exemestane, Fulvestrant, Letrozole, Palbociclib, Radiation Therapy, Tamoxifen
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Atlanta, Georgia • Augusta, Georgia • Columbus, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 6, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

NCT00728949
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
IMC-A12 (cixutumumab), tamoxifen, Anastrozole, Letrozole, Exemestane, Fulvestrant
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
9
States / cities
Scottsdale, Arizona • Chicago, Illinois • Westwood, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 6, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

NCT02788201
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
Interventions
75 approved agents, COXEN
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 6, 2026, 1:04 PM EDT
Recruiting Phase 2 Interventional

Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy

NCT05472792
View directory record Official record
Conditions
Breast Cancer, Quality of Life
Interventions
Accelerated Partial Breast Irradiation (APBI), tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
Radiation · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

ER Reactivation Therapy for Breast Cancer

NCT02188745
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
17B-estradiol, Letrozole, Anastrozole, Exemestane
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Springfield, Massachusetts • Rochester, Minnesota • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

NCT06001762
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
Interventions
Abemaciclib, Tamoxifen, Anastrozole, Letrozole, Exemestane, LHRH Agonist
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Stamford, Connecticut • Brewer, Maine • Scarborough, Maine + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors

NCT01272570
View directory record Official record
Conditions
Breast Cancer, Xerostomia
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 6, 2026, 1:04 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake

NCT02517593
View directory record Official record
Conditions
Breast Cancer
Interventions
Polygenic Risk Score
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 6, 2026, 1:04 PM EDT
Completed No phase listed Observational Results available

Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

NCT01896050
View directory record Official record
Conditions
Breast Cancer, Arthralgia, Obesity
Interventions
anastrozole, letrozole, exemestane, Tamoxifen
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 6, 2026, 1:04 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

NCT01272037
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
Interventions
Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
5,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1435
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

NCT03554044
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
Interventions
Anastrozole, Exemestane, Fulvestrant, Letrozole, Paclitaxel, Talimogene Laherparepvec, Tamoxifen, Nab paclitaxel, Gemcitabine, Carboplatin
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 6, 2026, 1:04 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

NCT04059484
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
Amcenestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
Birmingham, Alabama • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 6, 2026, 1:04 PM EDT
Recruiting Phase 2 Interventional

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

NCT06361940
View directory record Official record
Conditions
Breast Cancer
Interventions
Aromatase inhibitors or tamoxifen
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 6, 2026, 1:04 PM EDT